{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:56:54Z","timestamp":1770836214059,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"DOI":"10.7759\/cureus.83323","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:51:43Z","timestamp":1746186703000},"source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Low-Dose Interleukin-2 Therapy in Systemic Lupus Erythematosus: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Murad A","family":"Akkur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuha A","family":"Areeshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim Y","family":"Haqawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed A","family":"AlHabji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed H","family":"Altaher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanan A","family":"Jawkhab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maram M","family":"Fageehi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulrahman A","family":"Moafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed I","family":"Ismael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nouf A","family":"Al Alhadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos GC","year":"2011","unstructured":"Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011, 365:2110-21. 10.1056\/NEJMra1100359","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update \u03bfn the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis A","year":"2021","unstructured":"Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update \u03bfn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021, 80:14-25. 10.1136\/annrheumdis-2020-218272","journal-title":"Ann Rheum Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0903158107","article-title":"Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus","volume":"107","author":"Humrich JY","year":"2010","unstructured":"Humrich JY, Morbach H, Undeutsch R, et al.. Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc Natl Acad Sci U S A. 2010, 107:204-9. 10.1073\/pnas.0903158107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.03.019","article-title":"Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor","volume":"30","author":"Miyara M","year":"2009","unstructured":"Miyara M, Yoshioka Y, Kitoh A, et al.. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009, 30:899-911. 10.1016\/j.immuni.2009.03.019","journal-title":"Immunity"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nri3823","article-title":"The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases","volume":"15","author":"Klatzmann D","year":"2015","unstructured":"Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol. 2015, 15:283-94. 10.1038\/nri3823","journal-title":"Nat Rev Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg M","year":"2019","unstructured":"Rosenzwajg M, Lorenzon R, Cacoub P, et al.. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis. 2019, 78:209-17. 10.1136\/annrheumdis-2018-214229","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He J","year":"2020","unstructured":"He J, Zhang R, Shao M, et al.. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2020, 79:141-9. 10.1136\/annrheumdis-2019-215396","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207776","article-title":"Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus","volume":"75","author":"von Spee-Mayer C","year":"2016","unstructured":"von Spee-Mayer C, Siegert E, Abdirama D, et al.. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann Rheum Dis. 2016, 75:1407-15. 10.1136\/annrheumdis-2015-207776","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.07.016","article-title":"Interleukin-2 immunotherapy reveals human regulatory T\u00a0cell subsets with distinct functional and tissue-homing characteristics","volume":"57","author":"Raeber ME","year":"2024","unstructured":"Raeber ME, Caspar DP, Zurbuchen Y, et al.. Interleukin-2 immunotherapy reveals human regulatory T\u00a0cell subsets with distinct functional and tissue-homing characteristics. Immunity. 2024, 57:2232-2250.e10. 10.1016\/j.immuni.2024.07.016","journal-title":"Immunity"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03388-5","article-title":"Predictive biomarkers for low-dose IL-2 therapy efficacy in systemic lupus erythematosus: a clinical analysis","volume":"26","author":"Feng R","year":"2024","unstructured":"Feng R, Xiao X, Huang B, et al.. Predictive biomarkers for low-dose IL-2 therapy efficacy in systemic lupus erythematosus: a clinical analysis. Arthritis Res Ther. 2024, 26:180. 10.1186\/s13075-024-03388-5","journal-title":"Arthritis Res Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/jech.52.6.377","article-title":"The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions","volume":"52","author":"Downs SH","year":"1998","unstructured":"Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998, 52:377-84. 10.1136\/jech.52.6.377","journal-title":"J Epidemiol Community Health"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30107-9","article-title":"Low-dose IL-2 for patients with systemic lupus erythematosus","volume":"1","author":"He J","year":"2019","unstructured":"He J, Sun X, Li Z. Low-dose IL-2 for patients with systemic lupus erythematosus. Lancet Rheumatol. 2019, 1:203. 10.1016\/S2665-9913(19)30107-9","journal-title":"Lancet Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30018-9","article-title":"Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial","volume":"1","author":"Humrich JY","year":"2019","unstructured":"Humrich JY, von Spee-Mayer C, Siegert E, et al.. Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. Lancet Rheumatol. 2019, 1:44-54. 10.1016\/S2665-9913(19)30018-9","journal-title":"Lancet Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2478\/rir-2023-0021","article-title":"Low-dose interleukin-2 therapy in systemic lupus erythematosus","volume":"4","author":"La Cava A","year":"2023","unstructured":"La Cava A. Low-dose interleukin-2 therapy in systemic lupus erythematosus. Rheumatol Immunol Res. 2023, 4:150-6. 10.2478\/rir-2023-0021","journal-title":"Rheumatol Immunol Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105143","article-title":"Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis","volume":"365","author":"Saadoun D","year":"2011","unstructured":"Saadoun D, Rosenzwajg M, Joly F, et al.. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011, 365:2067-77. 10.1056\/NEJMoa1105143","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002139","article-title":"Regulatory T cell responses in participants with type 1 diabetes after a single dose of interleukin- 2: a non-randomised, open label, adaptive dose-finding trial","volume":"13","author":"Todd JA","year":"2016","unstructured":"Todd JA, Evangelou M, Cutler AJ, et al.. Regulatory T cell responses in participants with type 1 diabetes after a single dose of interleukin- 2: a non-randomised, open label, adaptive dose-finding trial. PLoS Med. 2016, 13:e1002139. 10.1371\/journal.pmed.1002139","journal-title":"PLoS Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He J","year":"2016","unstructured":"He J, Zhang X, Wei Y, et al.. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016, 22:991-3. 10.1038\/nm.4148","journal-title":"Nat Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth J","year":"2011","unstructured":"Koreth J, Matsuoka K, Kim HT, et al.. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011, 365:2055-66. 10.1056\/NEJMoa1108188","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2013.02.005","article-title":"IL-2 therapy in type 1 diabetes: \"trials\" and tribulations","volume":"149","author":"Long SA","year":"2013","unstructured":"Long SA, Buckner JH, Greenbaum CJ. IL-2 therapy in type 1 diabetes: \"trials\" and tribulations. Clin Immunol. 2013, 149:324-31. 10.1016\/j.clim.2013.02.005","journal-title":"Clin Immunol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.504","article-title":"Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata","volume":"150","author":"Castela E","year":"2014","unstructured":"Castela E, Le Duff F, Butori C, et al.. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol. 2014, 150:748-51. 10.1001\/jamadermatol.2014.504","journal-title":"JAMA Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/368036-efficacy-and-safety-of-low-dose-interleukin-2-therapy-in-systemic-lupus-erythematosus-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:51:44Z","timestamp":1746186704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/368036-efficacy-and-safety-of-low-dose-interleukin-2-therapy-in-systemic-lupus-erythematosus-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.83323","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}